Global Secukinumab Market Trends & Forecast 2024-2030

Market Outlook

The Secukinumab market was valued at USD 5,389 Million in 2023 and is projected to grow to USD 8,445 Million by 2034, with a compound annual growth rate (CAGR) of 4.3% from 2024 to 2030. Secukinumab is a type of human monoclonal antibody that works by selectively targeting interleukin-17A (IL-17A), which is a significant pro-inflammatory cytokine that plays a role in autoimmune diseases. It's mainly used to treat conditions like moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. By reducing inflammation, it helps alleviate symptoms such as pain, swelling, and skin lesions. As an advanced form of biologic therapy, it has earned recognition for its effectiveness and safety, making it a top choice in the field of immunology.

The market for Secukinumab is showing promising potential for growth. One of the primary factors driving this is the rising number of people diagnosed with autoimmune disorders worldwide. This trend is supported by greater awareness among patients and healthcare providers, which is leading to more diagnoses. Additionally, advancements in biologic treatments, as well as emerging markets—especially in regions like Asia-Pacific and Latin America—present exciting opportunities for expansion.

There’s also a trend toward developing new combination therapies and innovative formulations that target a wider range of conditions, which can further boost growth prospects. The development of biosimilars, particularly as patents expire, is another opportunity to make this treatment more accessible to more patients and broaden its user base. Strong clinical data continues to demonstrate its long-term effectiveness, encouraging healthcare providers to adopt it even as competition increases. Moreover, collaborations between pharmaceutical companies and research institutions are paving the way for new applications and deeper market penetration.

Key Insights

North America accounted for the largest share of the Secukinumab market at 47.29% in 2023. North America, especially the United States, has a significant share of the secukinumab market. This dominance is due to a high prevalence of autoimmune disorders, a well-developed healthcare infrastructure, and favorable insurance coverage for biologic therapies.

In terms of Indication, the plaque psoriasis accounted for a major share of 67.81%in 2023. The segment of the global secukinumab market that focuses on plaque psoriasis is the largest. This is mainly because plaque psoriasis is the most common type of psoriasis, affecting more than 90% of people who have the condition. Its high prevalence and the significant impact it has on patients' quality of life are key factors driving the demand for effective treatments like secukinumab in this area.

Market Dynamics

Increasing cases of conditions like psoriasis, ankylosing spondylitis, and psoriatic arthritis are driving demand for secukinumab.

Autoimmune diseases like psoriasis, ankylosing spondylitis, and psoriatic arthritis are becoming increasingly common, and this rise is driving a greater demand for secukinumab. These chronic conditions can lead to severe symptoms, making it tough for people to enjoy their everyday lives. Secukinumab, which works by inhibiting IL-17A, targets the inflammation at the root of these diseases, helping to relieve symptoms and improve long-term health outcomes.

Take psoriasis, for instance. It’s a widespread autoimmune skin condition that affects millions of people around the world. Those with moderate to severe forms often find that traditional treatments either don’t work very well or come with unpleasant side effects, pushing them to look for more effective biologic options like secukinumab. Similarly, conditions like ankylosing spondylitis, which primarily impacts the spine, and psoriatic arthritis, which affects both skin and joints, are being diagnosed more frequently thanks to better awareness and improved diagnostic methods.

In clinical trials, secukinumab has demonstrated impressive effectiveness for these conditions, providing quick relief from symptoms and maintaining control over the disease, all while generally being well-tolerated. This strong evidence, combined with an increase in awareness about these diseases, is encouraging healthcare professionals to consider secukinumab as a primary treatment or an add-on option.

Also, with the growing impact of autoimmune diseases, governments and healthcare organizations are increasingly focusing on advanced treatment options. Secukinumab, with its established success and ability to meet critical patient needs, is in a strong position to thrive within this shifting landscape, contributing to its rising popularity in the global market.

The expensive nature of biologic therapies like secukinumab limits accessibility in regions with limited healthcare funding.

The high price of biologic therapies, like secukinumab, really makes it hard for many people to access these treatments, especially in places where healthcare resources are tight. Biologics are usually more expensive than traditional medications because creating them is complex and requires advanced technology. Secukinumab, which is a monoclonal antibody designed to target interleukin-17A, offers cutting-edge treatment for autoimmune diseases, but it comes with a hefty price tag.

In countries with limited healthcare funding—think developing nations or systems that are struggling to keep up—the cost of secukinumab can be a huge barrier. Patients in those regions often find it difficult to get this potentially life-changing treatment, as healthcare budgets typically prioritize essential services and more affordable options. Even in wealthier markets, where insurance might cover part of the cost, copayments and out-of-pocket expenses can still leave some individuals unable to afford it.

Also, the ongoing expense of biologic therapies is another challenge. Since they usually require long-term treatment, this can put a significant strain on both healthcare systems and patients' finances. It creates a situation where only those with ample resources or comprehensive insurance can take advantage of secukinumab, leaving many others without access to the most effective treatment options available.

Segmental Analysis

Based on Indication, Secukinumab market is segmented into Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis.

Plaque psoriasis is the most common form of psoriasis, which is a chronic autoimmune condition that leads to red, scaly patches on the skin. Because it's so prevalent worldwide, plaque psoriasis plays a major role in driving the demand for Secukinumab. More and more people are being diagnosed with moderate to severe plaque psoriasis, and this growing patient population is pushing the need for more effective treatment options.

Secukinumab is a monoclonal antibody that specifically targets interleukin-17A. It's shown impressive results in treating plaque psoriasis, significantly alleviating symptoms and improving patients' quality of life compared to traditional treatments like topical steroids or phototherapy.

Awareness about health issues, better diagnostic practices, and improvements in treatment options are all contributing to the rising use of Secukinumab. Many patients are choosing biologics because of their effectiveness and the long-lasting relief they provide. Plus, the growing number of regulatory approvals and the increased availability of Secukinumab in various markets mean that more people can access this treatment.

The success of Secukinumab in managing plaque psoriasis is backed by positive outcomes from clinical trials, showcasing its rapid onset of action and the potential for lasting remission. Because of these factors, plaque psoriasis continues to be the leading condition treated with Secukinumab, greatly influencing its growth in the market.

Regional Landscape

In the context of regional analysis, the Secukinumab market includes North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

The market size of the North America was valued at USD 2,548 Million in 2023 and is expected to reach USD 3,871 Million by 2030, with a CAGR of 4.0% during the forecast period. North America stands out in the global secukinumab market for a number of reasons. One of the biggest factors is the region's advanced healthcare system, which provides broad access to treatments like secukinumab. This is especially vital for individuals dealing with chronic conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. Thanks to widespread insurance coverage, many patients can afford these costly biologic therapies, which has led to a higher use of secukinumab compared to other parts of the world.

Another key reason for North America's strong position is its vibrant research and development scene. Many leading pharmaceutical companies in the U.S. and Canada are actively involved in innovating and finding new applications for secukinumab through ongoing clinical trials. This has resulted in the drug being approved for multiple uses beyond just psoriasis, broadening its market reach significantly.

Also, the high level of healthcare spending in North America supports the quick adoption of advanced therapies. Since secukinumab is an expensive biologic treatment, it thrives in an environment that prioritizes cutting-edge medical solutions. Plus, the region's efficient regulatory framework allows for faster approval processes, helping patients gain access to new treatments more quickly. Overall, these factors contribute to North America’s leading role in the secukinumab market.

Competitive Landscape

Some of the major companies operating within the Secukinumab market are: Novartis.   

Table of Contents

FAQ (Frequently Asked Questions)